Interferon Alpha in the Management of Metastatic Neuroendocrine Tumors: A Retrospective Study in 37 Patients Abstract #738

Introduction: Interferon alpha (IFNα) has not been popular due to perceived lack of efficacy and toxicity profile. Current molecular targeted therapies demonstrate only modest anti-tumor effect with not insignificant toxicity.
Aim(s): To perform a retrospective analysis of IFNα in patients with metastatic NET assessing efficacy and toxicity.
Materials and methods: Thirty-seven patients treated with minimum IFNα 3 million units x 3/week. Mean age 58.6 (24-88) yrs; 26:11 m:f; 21 midgut, seven pancreatic, one hindgut, one bronchial, one thymic and six unknown. Histology: G1 49%; G2 41%; G3 5%: unknown 5%. Seventy-six percent also on somatostatin analogue. Sixty-five percent had progressive disease (PD). CT/MRI imaging; urine 5HIAA and plasma chromagranin A (CgA) and toxicities were recorded.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: PROF Martyn Caplin
Keywords: Interferon

To read results and conclusion, please login ...

Further abstracts you may be interested in

#768 Long-Term Haematological and Renal Toxicity of 90Yttrium-DOTA-Octreotate in the Treatment of Advanced Neuroendocrine Tumors(NETs)
Introduction: Peptide receptor radiation therapy (PRRT) is an established treatment for advanced NETs. Renal/haematological toxicity are recognised adverse effects.
Conference: 10th Annual ENETS Conference (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: DR VINCENT Cheung
#844 Variation Between Chromogranin A Assays in the Diagnosis of Gastric Carcinoid Type 1
Introduction: Chromogranin A (CgA) is not very accurate for the diagnosis of gastric carcinoid type1 (GC1). Clinical interpretation of CgA results may be affected by the heterogeneity between CgA assays. The commercial CgA assay, DAKO (DAKO, Denmark A/S, Glostrup, Denmark) is an ELISA which recognizes a 23 kD C terminal fragment of CgA; the Imperial Supra-regional Assay Service radioimmunoassay (SAS Hammersmith Hospital, Imperial College, London) is a competitive radioimmunoassay raised against the whole pancreastatin molecule.
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: MD Roberta E Rossi
#1712 Epidemiological Factors at Diagnosis in a Large Cohort of Patients with Pancreatic Neuroendocrine Tumours
Introduction: Pancreatic neuroendocrine tumours(pNETs) are among the most frequent NETs with an increasing incidence.However,recent epidemiological data reports are limited.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr Apostolos Koffas
#1713 Predictive Factors for Survival in Patients with Pancreatic Neuroendocrine Tumours
Introduction: Pancreatic neuroendocrine tumours(pNETs) comprise a heterogeneous group of neoplasms with rising incidence.However,prognosticators at diagnosis(Dx) are limited.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr Apostolos Koffas
#151 Rationale for combining mTOR with other targeted agents in the treatment of neuroendocrine tumors
Introduction: Advanced neuroendocrine tumors (NETs) are aggressive and incurable with standard treatment. Many cellular targets are being evaluated in this patient population, including mammalian target of rapamycin (mTOR), a kinase that is the central regulator of several signaling pathways related to cell growth, angiogenesis, and bioenergetics. Because mTOR serves as a neoplastic switch activated by many cancer-related mutations, mTOR inhibition may have broad efficacy across tumor types, including NETs. Somatostatin analogs (SSAs) have long been used to treat carcinoid symptoms in NET patients. The SSA octreotide long-acting release (LAR) demonstrated significant antitumor effects against advanced midgut NETs in the phase III PROMID study.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Kjell Öberg
Authors: Öberg K, Yao J C, ...
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.